Sökning: "minimal residual disease"
Visar resultat 1 - 5 av 33 avhandlingar innehållade orden minimal residual disease.
Sammanfattning : Traditionally, response to treatment in hematological malignancies is evaluated by light microscopy of bone marrow (BM) smears, but due to more effective therapies more sensitive methods are needed. Today, detection of minimal residual disease (MRD) using immunological and molecular techniques can be 100 times more sensitive than morphology. LÄS MER
Sammanfattning : Acute myeloid leukemia (AML) is the most common form of acute leukemia and generally associated with a poor prognosis. For both children and adults, the treatment is based on chemotherapy. Allogeneic hematopoietic stem cell transplant (alloHCT) is reserved for patients with intermediate or high risk of relapse, due to its associated risks. LÄS MER
Sammanfattning : The investigation of minimal residual disease (MRD) with multiparameter flow cytometry (FC) immunophenotyping has proven to be a powerful approach for disease monitoring in patients with acute leukemia (AL). This technique mainly relies on the identification of minor leukemic cell populations that can be discriminated from their normal counterparts on the basis of phenotypic aberrancies observed at diagnosis. LÄS MER
4. The methodology and significance of minimal residual disease detection after allogeneic stem cell transplantation
Sammanfattning : Allogeneic stem cell transplantation (SCT) is the choice of therapy for leukemia patients who respond poorly to conventional chemotherapy. Despite high remission rates after SCT, relapse of the underlying disease remains one of the most frequent causes of treatment failure. LÄS MER
5. Detection of immunoglobulin heavy chain gene rearrangement with PCR for MRD analysis in lymphoproliferative disorders
Sammanfattning : Immunoglobulin heavy chain (IGH) gene rearrangement occurs during early B-lymphocyte differentiation, assembling the different IGH gene segments to a functional gene, which can serve as a marker for study of lineage association and detection of Minimal Residual Disease (MRD) in clonal diseases deriving from B-lymphocytes or their early differentiation stages. Use of a molecular marker for the leukemic cells could help improve treatment by monitoring therapeutic efficacy, predicting relapse, and identifying very small amounts of tumour cells contaminating autografts after purging or enrichment of stem cells. LÄS MER